Mankind Pharma Ltd

Mankind Pharma Ltd has witnessed a notable 15.11% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this surge, the stock underperformed its sector and the broader Sensex, reflecting a complex interplay between bullish bets and short-term profit-taking.

Mankind Pharma Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 16.23% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a slight price dip of 0.72% on 23 Jun 2026, the stock’s underlying metrics and trading volumes suggest a complex interplay of bullish and bearish bets among market participants.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a marginal decline in the stock price, the pharmaceutical mid-cap’s derivatives market shows signs of increased speculative interest, raising questions about potential directional bets and future price movements.

Mankind Pharma Ltd has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The pharmaceutical mid-cap, currently rated a Buy with a Mojo Score of 72.0, has been gaining steadily over the past five days, reflecting growing investor confidence despite a slight underperformance relative to its sector.

Mankind Pharma Ltd has witnessed a notable 12.48% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor sentiment. This surge accompanies a steady price rally and rising volumes, suggesting a growing bullish bias among traders in the mid-cap pharmaceutical stock.

Mankind Pharma Ltd has witnessed a significant surge in open interest (OI) in its derivatives segment, reflecting heightened market activity and bullish positioning among investors. The stock’s recent outperformance, coupled with rising volumes and sustained gains, suggests growing confidence in the pharmaceuticals and biotechnology mid-cap’s near-term prospects.

The Sensex edged up 0.42% on 22 Jun 2026, but Mankind Pharma Ltd outpaced the broader market with a 5.14% gain, reaching an intraday high of Rs 2536.55. This 3.59 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector signals a distinctly stock-specific rally rather than a market-wide lift.

Mankind Pharma Ltd has been upgraded from a Hold to a Buy rating following a comprehensive reassessment of its technical indicators, financial trends, valuation metrics, and overall quality. The upgrade reflects improved market sentiment, robust quarterly financials, and a bullish technical outlook, positioning the mid-cap pharmaceutical company favourably against its peers and broader market benchmarks.

Mankind Pharma Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underpinned by a combination of positive signals from key technical indicators including MACD, Bollinger Bands, and moving averages, suggesting an improved outlook for the mid-cap pharmaceutical player amid mixed sector and market conditions.

Mankind Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 13 June 2026, providing investors with the most up-to-date view of the stock’s fundamentals and market performance.

Mankind Pharma Ltd has experienced a subtle but noteworthy shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish outlook. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and volume-based metrics, reflecting a nuanced market sentiment for the mid-cap pharmaceutical player.

The 50-day moving average has crossed above the 200-day moving average for Mankind Pharma Ltd, signalling a golden cross on 11 Jun 2026. Yet, the broader technical landscape presents a nuanced picture, with weekly indicators showing both bullish and mildly bearish signals, and the monthly timeframe failing to fully confirm the crossover. This divergence invites a closer examination of the signal's reliability.

Rs 2,000 put options on Mankind Pharma Ltd attracted 4,869 contracts on 11 Jun 2026, despite the stock trading robustly at Rs 2,405.60. This strike price sits nearly 17% below the current market price, suggesting the put activity may be more about protection than outright bearish conviction.

Mankind Pharma Ltd has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bearish stance as of early June 2026. Despite a modest decline in daily price and a downgrade in its Mojo Grade from Buy to Hold, the stock continues to demonstrate resilience relative to the broader market, supported by a complex interplay of technical indicators across weekly and monthly timeframes.

Mankind Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend as of early June 2026. Despite a recent downgrade in its Mojo Grade from Buy to Hold, the stock continues to outperform the Sensex over multiple time horizons, supported by a complex interplay of technical indicators that suggest cautious optimism for investors.

Mankind Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Mankind Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish to a mildly bearish trend as of early June 2026. This transition is underscored by mixed signals from key technical indicators including MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced outlook for investors amid recent price volatility and sector dynamics.